456 related articles for article (PubMed ID: 27493100)
1. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
2. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178
[TBL] [Abstract][Full Text] [Related]
3. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy.
Nishimura M; Sasaki T; Ohishi A; Oishi M; Kono S; Totani Y; Kato Y; Noto Y; Misaki S; Higashi K; Shimada F; Wakasugi H; Inoue K; Hoshiyama Y; Yamada K
Clin Nephrol; 2001 Aug; 56(2):96-103. PubMed ID: 11522101
[TBL] [Abstract][Full Text] [Related]
5. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
6. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
8. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
9. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
10. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
Ito S; Kagawa T; Saiki T; Shimizu K; Kuroda S; Sano Y; Umeda Y
Clin J Am Soc Nephrol; 2019 Mar; 14(3):354-363. PubMed ID: 30755452
[TBL] [Abstract][Full Text] [Related]
12. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
[TBL] [Abstract][Full Text] [Related]
13. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
15. Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.
Swoboda PP; McDiarmid AK; Erhayiem B; Ripley DP; Dobson LE; Garg P; Musa TA; Witte KK; Kearney MT; Barth JH; Ajjan R; Greenwood JP; Plein S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28716801
[TBL] [Abstract][Full Text] [Related]
16. Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial.
Liyanage P; Lekamwasam S; Weerarathna TP; Liyanage C
J Postgrad Med; 2018; 64(1):10-15. PubMed ID: 29386413
[TBL] [Abstract][Full Text] [Related]
17. Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
Afghahi H; Miftaraj M; Svensson AM; Hadimeri H; Gudbjörnsdottir S; Eliasson B; Svensson MK;
J Diabetes Complications; 2013; 27(3):229-34. PubMed ID: 23246248
[TBL] [Abstract][Full Text] [Related]
18. Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study.
Endo K; Saiki A; Yamaguchi T; Sakuma K; Sasaki H; Ban N; Kawana H; Nagayama D; Nagumo A; Ohira M; Oyama T; Murano T; Miyashita Y; Yamamura S; Suzuki Y; Shirai K; Tatsuno I
J Atheroscler Thromb; 2013; 20(5):494-502. PubMed ID: 23363981
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Morikawa A; Ishizeki K; Iwashima Y; Yokoyama H; Muto E; Oshima E; Sekiguchi M; Miura T; Itoh H; Haneda M
Clin Exp Nephrol; 2011 Dec; 15(6):848-53. PubMed ID: 21823043
[TBL] [Abstract][Full Text] [Related]
20. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
